Mechanistic model based on artificial intelligence for the reuse of drugs against SARS-CoV-2 infection

The rapid spread of SARS-CoV-2, a new virus, has gripped healthcare systems without adequate therapies. Although the development of a new drug is not feasible in the short term, the solution of reusing drugs with other indications would bring the availability of new therapies closer. Computational approaches have proven to be faster and cheaper than experimental ones. Among these, those based on mechanistic models, which allow inferring cause-effect relationships, have shown greater effectiveness than traditional solutions such as virtual screening or others. We propose the use of a mechanistic model based on artificial intelligence that has already demonstrated its effectiveness in rare diseases for the reuse of drugs for Covid-19.